Clinical Trial Update: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating an NY-ESO-1 vaccine therapy with or without sirolimus in patients whose tumors express NY-ESO-1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Breast Cancer
• Colorectal Cancer
• Esophageal Cancer
• Glioblastoma
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• NY-ESO-1 vaccine
• Sirolimus (Sirolimus)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Status: COMPLETED